About Avicanna
Avicanna is a company based in Toronto (Canada) founded in 2016 by Aras Azadian. Avicanna has raised $5.94 million across 19 funding rounds from investors including Tasly, Orthogonal Thinker and Barn Invest. The company has 55 employees. Avicanna offers products and services including Medical Cannabis Products, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients. Avicanna operates in a competitive market with competitors including ZYUS Life Sciences, Sanity Group, Terraflos, Little Green Pharma and IMCannabis, among others.
- Annual Revenue$18.61 M (USD)0.08as on Dec 31, 2025
- Net Profit-$2.07 M (USD)28.77as on Dec 31, 2025
- EBITDA-$1.44 M (USD)41.41as on Dec 31, 2025
- Total Equity Funding$5.94M (USD)
in 19 rounds
- Latest Funding Round$220.35K (USD), Post-IPO
Feb 2026
- InvestorsTasly
& 2 more
- Employee Count55
Products & Services of Avicanna
Avicanna offers a comprehensive portfolio of products and services, including Medical Cannabis Products, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients.
Evidence-based cannabinoid formulations for medical use.
Developing cannabinoid-based drugs for health applications.
Cannabinoid ingredients for commercial pharmaceutical products.
Apps and channels of Avicanna
its YouTube channel Avicanna Media has 99 subscribers and 9 videos.
Videos from Avicanna
The most watched videos on Avicanna's YouTube channel, Avicanna Media (99 subscribers). Click a video to play it here.
More on Avicanna Media.
Funding Insights of Avicanna
Avicanna has successfully raised a total of $5.94M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $220.35 thousand completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.94M
- Total Rounds 19
- Last Round Post-IPO — $220,347
- First Round $1.19M
(May 2017)
- Investors Count 3
Latest 10 of 19 funding rounds of Avicanna with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $220,347 | Post-IPO | – | – | – |
| Jul 2025 | $729,667 | Post-IPO | – | – | – |
| Nov 2024 | $573,251 | Post-IPO | – | – | – |
| Aug 2024 | $1.47M | Post-IPO | – | – | – |
| Apr 2024 | $2.13M | Post-IPO | – | – | – |
| Aug 2023 | $1.1M | Post-IPO | – | – | – |
| Mar 2023 | $1.24M | Post-IPO | – | – | – |
| Nov 2022 | $626,762 | Post-IPO | – | – | – |
| Aug 2022 | $2.78M | Post-IPO | – | – | – |
| May 2022 | $1.18M | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in Avicanna
Avicanna has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Tasly, Orthogonal Thinker and Barn Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm & investment bank focused on plant science based companies | – | orthogonalthinker.com | Kihei, United States | |
Barn Invest is focused on greentech investments in Latin America. | – | barninvest.com.br | Sao Paulo, Brazil | |
Traditional Chinese medicines are manufactured and distributed globally. | 1994 | tasly.com | Tianjin, China |
Investor details for Avicanna
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avicanna
24 people are tracked at Avicanna (11 in leadership, 11 in board & advisors, 2 in team); the tracked headcount is 55.
| Name | Role | Group |
|---|---|---|
Aras Azadian | Co-Founder & CEO | Leadership |
Samantha Watt | VP of Scientific Affairs | Leadership |
Stephen Kim | Chief Legal Officer & General Counsel, Avicanna USA INC. | Leadership |
Karolina Urban | VP, Scientific & Medical Affairs | Leadership |
Brennan Kerr | VP, Commercialization | Leadership |
Jens Kramer | VP, European Operations | Leadership |
Ingrid Diaz | VP, Assistant General Counsel & Corporate Compliance Officer | Leadership |
Juan David Gonzalez | VP, Avicanna LATAM S.A.S. | Leadership |
Ingrid Lorena Diaz Baquero | Vice President, Assistant General Counsel & Corporate Compliance Officer | Leadership |
Nick Hilborn | Director Of Finance | Leadership |
Eric Cheung | Director Of Business Intelligence & Analytics | Leadership |
Chandra Panchal | Chairman | Board & advisors |
Giancarlo Davila | Director | Board & advisors |
Aline Masuda | Advisor | Board & advisors |
Mauricio Torres-Pradilla | Scientific Advisor | Board & advisors |
Humberto Reynales | Scientific Advisor | Board & advisors |
Eileen McCormack | Director | Board & advisors |
John McVicar | Director | Board & advisors |
Sheldon Inwentash | Advisor | Board & advisors |
Ori Tal | Advisor | Board & advisors |
4 more people are available in the full profile.
Complete people profiles for Avicanna
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Avicanna
Avicanna is a publicly listed company on the TSX with ticker symbol AVCN in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Jul 2019
- Listed onTSX: AVCN
- Listed entityAvicanna Inc
- Exchange sectorHealth technology
- ISINCA05368K1003
- Share price0.12 CAD (+9.52% on the day) · 2026-10-09
- Market capitalisation15,454,143.00 CAD
- EPS (diluted, trailing year)-0.03 CAD
- Volume (last session)39,850
Financials of Avicanna
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 25.5M CAD | -2.8M CAD | -2.0M CAD |
| 2024 | 25.5M CAD | -4.0M CAD | -3.4M CAD |
| 2023 | 16.8M CAD | -7.9M CAD | -6.9M CAD |
| 2022 | 4.0M CAD | -13.4M CAD | -11.2M CAD |
| 2021 | 3.3M CAD | -16.8M CAD | -12.0M CAD |
Detailed financial statements for Avicanna
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Avicanna
4 dated milestones of Avicanna across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Avicanna is founded.
- Funding First funding round of $1.2M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $220K.
Competitors of Avicanna
Avicanna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ZYUS Life Sciences, Sanity Group, Terraflos, Little Green Pharma and IMCannabis, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| zyus.com | 2018 | Saskatoon, Canada | $19.5M | – | Cannabis-derived therapeutics for multiple indications are developed. | |
| sanitygroup.com | 2011 | Berlin, Germany | $108.79M | – | Developer of cannabinoid-based pharmaceuticals and well-being products | |
| terraflos.com | 2021 | Uruguay | $8M | – | Medical cannabis products are provided based on GMP processes. | |
| littlegreenpharma.com | 2016 | Perth, Australia | $1.91M | – | Manufacturer of medicinal cannabis for therapeutic use | |
| imcannabis.com | 2008 | Herzliya, Israel | – | – | Developer of medical cannabis products | |
| neocannbio.com | 2021 | Seoul, South Korea | $10.9M | – | Cannabinoid-based pharmaceuticals and production technologies are developed. | |
| aleafiahealth.com | 2007 | Vaughan, Canada | – | – | Cultivator and producer of cannabis plant for consumer wellness and research applications |
Detailed competitors of Avicanna
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Avicanna
The website of Avicanna (avicanna.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 13.5% vs previous month
Latest news on Avicanna
Complete news archive for Avicanna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Avicanna
10 companies that operate in the same segment as Avicanna (Cannabis Health Tech Ecosystem), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Cannabis products are provided to support consumer wellness and health. | 2013 | Smiths Falls, Ontario, Canada | – | USD 204.24 M | 960 | |
Online marketplace platform for cannabis traders | 2015 | New York, New York, United States | USD 195.4 M | – | – | |
Loyalty and marketing solutions for cannabis dispensaries are provided. | 2012 | West Palm Beach, Florida, United States | USD 25.79 M | USD 22.83 M | – | |
An online marketplace for cannabis products is operated. | 2017 | Bend, Oregon, United States | USD 603 M | – | 137 | |
Online platform for cannabis strains, reviews, and ratings | 2010 | Seattle, Washington, United States | USD 40.7 M | – | – | |
Provider of cannabis products, brands, and international business development investments | 2013 | Moncton, New Brunswick, Canada | – | USD 186.16 M | 898 | |
ERP software is offered via cloud platform for cannabis operations. | 2018 | Boston, Massachusetts, United States | – | USD 110.08 M | 313 | |
Online marketplace connecting licensed cannabis vendors and dispensaries | 2015 | Chicago, Illinois, United States | USD 22.57 M | – | – | |
Enterprise software is provided for cannabis dispensary management. | 2016 | Oakland, California, United States | USD 75.5 M | USD 148.97 K | 97 | |
Proprietary medical cannabis strains are developed and offered. | 2014 | Maryland Heights, Missouri, United States | USD 156 M | – | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Avicanna
Avicanna was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Avicanna is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Aras Azadian is the current CEO of Avicanna. They have also founded this company.
Avicanna is a funded company, having raised a total of $5.94M across 19 funding rounds to date. The company's 1st funding round was a Post-IPO of $1.18M, raised on May 2017.
Avicanna has 55 employees.
Annual revenue of Avicanna is $18.61M as on Dec 31, 2025.
Avicanna was founded in 2016 in Toronto, Canada, as a developer in the cannabinoid sector. Advanced formulations and delivery systems based on plant-derived cannabinoids are created for medical applications and consumer goods. Solutions are marketed through channels such as derma-cosmetics, phytotherapeutics, and pharmaceuticals, targeting diverse markets with a focus on therapeutic and wellness products.
Avicanna's top competitors include ZYUS Life Sciences, Neocannbio and IMCannabis.
Avicanna offers Medical Cannabis Products, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients.
Yes, Avicanna is publicly traded on TSX under the ticker symbol AVCN.
Avicanna has 3 investors. Key investors include Tasly, Orthogonal Thinker, and Barn Invest.
Avicanna operates through Avicanna Inc..